Prophylaxis
发表于 2025-3-28 17:03:49
Interleukin-10 in cerebral ischemia and strokees of death and disability in industrialized countries. Early (< 3 h) treatment with tissue plasminogin activator (t-PA) was approved in 1996 for the treatment of acute stroke . Nevertheless, the therapeutic challenge remains to determine what specific pharmacologic or nonpharmagologic interventi
Neutral-Spine
发表于 2025-3-28 21:50:17
http://reply.papertrans.cn/47/4647/464688/464688_42.png
NAV
发表于 2025-3-28 23:28:12
http://reply.papertrans.cn/47/4647/464688/464688_43.png
可忽略
发表于 2025-3-29 06:46:19
http://reply.papertrans.cn/47/4647/464688/464688_44.png
使痛苦
发表于 2025-3-29 09:53:27
http://reply.papertrans.cn/47/4647/464688/464688_45.png
FECK
发表于 2025-3-29 11:36:56
http://reply.papertrans.cn/47/4647/464688/464688_46.png
ALERT
发表于 2025-3-29 18:42:22
http://reply.papertrans.cn/47/4647/464688/464688_47.png
大雨
发表于 2025-3-29 20:36:07
Book 2001ible explanation is that research and pharmacological management have focused on very early events in brain ischemia. New research has shown that brain ischemia and trauma elicit strong inflammatory reactions driven by both external and brain cells. The recognition of inflammation as a fundamental r
BOON
发表于 2025-3-30 02:19:22
http://reply.papertrans.cn/47/4647/464688/464688_49.png
冲击力
发表于 2025-3-30 06:17:39
Interleukin-1 and IL-1 receptor antagonist in stroke: mechanisms and potential therapeuticssts that these events are regulated by extracellular ATP acting on purinergic P2x7receptors; pharmacological activation of these receptors leads to IL-1β cleavage and release from macrophages and microglia .